

AUA  
2024  
*San Antonio*

MAY 3-6



# RESTART

Anders Kjellman, MD, PhD,  
Karolinska University Hospital  
Stockholm  
Sweden




# RESection or Thermal Ablation for Renal Tumours

Multicenter randomised trial to compare thermal ablation and partial nephrectomy for kidney cancer lesions  $\leq 3$  cm


## **Hypothesis:**

Ablation of small kidney cancer lesions have less complications compared to surgery




# Inclusion criteria

- Age 18-99
- Indication and clinically possible to do both ablative treatment and PN
- Tumour size  $\leq 3$  cm
- Clinical stage T1a
- Kidney cancer histology ISUP grade I-III
- M0



# Exclusion criteria

- M1
- Synchronous kidney tumours
- Other metastasized malignancy last five years
- ISUP IV or sarcomatoid features in biopsy



# Primary endpoints

- Surgical complications at 30 and 90 days (CD grade 2-5)
- Radiological signs of a residual tumour at the 6-month follow-up



# Secondary outcomes

- Cancer specific survival
- Overall survival
- Recurrence free survival
- Change in eGFR after one year
- Quality of life (EORTC-QLQ 30)
- Pain medication
- Length of hospital stay

# Follow-up

According to the Swedish guidelines with radiology and lab tests up to 5 years

Follow up for vital status and recurrences up to 10 years

# Timelines

Study opened April 24 2024

First patient included April 25 2024

End of inclusion fall 2028

First results 2029

ClinicalTrials.gov ID: NCT06278506

Thank You!